RCD方案在多发性骨髓瘤维持治疗中的临床研究  

Clinical study of RCD regimen in maintenance treatment of multiple myeloma

作　　者：吕殿亮[1] 石琳[1] 吴艺[1] 张宽顺 卢金金[1] 曹天星 程志[1] LYU Dian-liang;SHI Lin;WU Yi(Department of Hematology,Henan Provincial Hospital of Traditional Chinese Medicine,Zhengzhou 450000,China)

机构地区：[1]河南省中医院血液内科,450000

出　　处：《中国实用医药》2022年第2期148-151,共4页China Practical Medicine

摘　　要：目的对来那度胺联合环磷酰胺,地塞米松(RCD方案)在多发性骨髓瘤维持治疗中的临床研究。方法78例多发性骨髓瘤患者,以随机信封分组法分为参比组和试验组,每组39例。参比组应用常规化疗方案治疗。试验组应用RCD方案治疗。比较两组患者治疗后的相关指标(M-蛋白、β_(2)-微球蛋白、CD4^(+)、CD4^(+)/CD8^(+))、临床疗效、药物不良反应发生情况。结果试验组患者治疗后的M-蛋白(17.39±6.08)g/L、β_(2)-微球蛋白(1.61±0.36)mg/L均低于参比组的(23.54±8.37)g/L、(2.25±0.63)mg/L,CD4^(+)(45.24±5.13)%、CD4^(+)/CD8^(+)(1.78±0.51)均高于参比组的(35.92±4.79)%、(1.32±0.44),差异均具有统计学意义(P<0.05)。试验组治疗总有效率87.18%高于参比组的64.10%,差异具有统计学意义(P<0.05)。试验组神经组织病变、嗜睡、便秘发生率低于参比组,血小板数量减少、中性粒细胞数量减少发生率高于参比组,差异均具有统计学意义(P<0.05)。结论在对多发性骨髓瘤患者进行治疗时,使用RCD方案治疗能够改善患者相关指标,提高临床疗效,降低神经组织病变、嗜睡、便秘等药物不良反应发生率,值得在临床上推广。Objective To study the clinical effect of Revlimid,cyclophosphamide and dexamethasone(RCD regimen)in maintenance treatment of multiple myeloma.Methods A total of 78 patients with multiple myeloma were divided into reference group and test group by random envelope grouping,with 39 cases in each group.The reference group was treated with conventional chemotherapy regimen,and the test group was treated with RCD regimen.The related indicators(M-protein,β_(2)-microglobulin,CD4^(+),CD4^(+)/CD8^(+)),clinical efficacy,and occurrence of adverse drug reactions after treatment were compared between the two groups.Results After treatment,the M-protein(17.39±6.08)g/L and β_(2)-microglobulin(1.61±0.36)mg/L of the test group were lower than(23.54±8.37)g/L and(2.25±0.63)mg/L of the reference group,and the CD4^(+)(45.24±5.13)%,CD4^(+)/CD8^(+)(1.78±0.51)were higher than(35.92±4.79)%,(1.32±0.44)of the reference group,and the difference was statistically significant(P<0.05).The total effective rate of treatment 87.18%in the test group was higher than 64.10%in the reference group,and the difference was statistically significant(P<0.05).The incidence of neuropathy,lethargy,and constipation of the test group was lower than that of the reference group,and the incidence of reduced platelet count and neutrophil count was higher than that of the reference group,and the differences were statistically significant(P<0.05).Conclusion In the treatment of patients with multiple myeloma,the use of RCD regimen can improve the relevant indicators of the patient,improve the clinical efficacy,and reduce the incidence of adverse drug reactions such as neuropathy,lethargy,and constipation.It is worthy of clinical promotion.

关 键 词：来那度胺 环磷酰胺 地塞米松 多发性骨髓瘤 

分 类 号：R733.3[医药卫生—肿瘤]